Messing with cancer therapy: how the melanoma phenotype predicts checkpoint inhibitor response

Signal Transduct Target Ther. 2024 Apr 1;9(1):76. doi: 10.1038/s41392-024-01785-5.

Authors

Svenja Meierjohann¹, Corine Bertolotto²

Affiliations

¹ Institute of Pathology, University of Würzburg, Würzburg, Germany. [email protected].
² University Côte d'Azur, Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020, Centre Méditerranéen de Médecine Moléculaire, Nice, France.

No abstract available

MeSH terms

Antibodies, Monoclonal
Humans
Melanoma* / drug therapy
Melanoma* / genetics
Phenotype
Skin Neoplasms*

Substances

Antibodies, Monoclonal

Grants and funding